Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

Zhao Chen, Takaaki Sasaki, Xiaohong Tan, Julian Carretero, Takeshi Shimamura, Danan Li, Chunxiao Xu, Yuchuan Wang, Guillaume O. Adelmant, Marzia Capelletti, Hyun Joo Lee, Scott J. Rodig, Christa Borgman, Seung Il Park, Hyeong Ryul Kim, Robert Padera, Jarrod A. Marto, Nathanael S. Gray, Andrew L. Kung, Geoffrey I. ShapiroPasi A. Jänne, Kwok Kin Wong

Research output: Contribution to journalArticle

Abstract

Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 13% of non-small cell lung cancer patients and rarely coexist with KRAS or EGFR mutations. To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises. In this model, the ALK kinase inhibitor TAE684 produced greater tumor regression and improved overall survival compared with carboplatin and paclitaxel, representing clinical standard of care. 18F-FDG-PET-CT scans revealed almost complete inhibition of tumor metabolic activity within 24 hours of TAE684 exposure. In contrast, combined inhibition of the PI3K/AKT and MEK/ERK1/2 pathways did not result in significant tumor regression. We identified EML4-ALK in complex with multiple cellular chaperones including HSP90. In support of a functional reliance, treatment with geldanamycin-based HSP90 inhibitors resulted in rapid degradation of EML4-ALK in vitro and substantial, albeit transient, tumor regression in vivo. Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement.

Original languageEnglish (US)
Pages (from-to)9827-9836
Number of pages10
JournalCancer Research
Volume70
Issue number23
DOIs
StatePublished - Dec 1 2010
Externally publishedYes

Fingerprint

Oncogene Fusion
Mitogen-Activated Protein Kinase Kinases
Phosphatidylinositol 3-Kinases
Lung Neoplasms
Neoplasms
Phosphotransferases
MAP Kinase Signaling System
Carboplatin
Fluorodeoxyglucose F18
Standard of Care
Paclitaxel
Oncogenes
Non-Small Cell Lung Carcinoma
anaplastic lymphoma kinase
Adenocarcinoma of lung
Therapeutics
Mutation
Survival

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Chen, Z., Sasaki, T., Tan, X., Carretero, J., Shimamura, T., Li, D., ... Wong, K. K. (2010). Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. Cancer Research, 70(23), 9827-9836. https://doi.org/10.1158/0008-5472.CAN-10-1671

Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. / Chen, Zhao; Sasaki, Takaaki; Tan, Xiaohong; Carretero, Julian; Shimamura, Takeshi; Li, Danan; Xu, Chunxiao; Wang, Yuchuan; Adelmant, Guillaume O.; Capelletti, Marzia; Lee, Hyun Joo; Rodig, Scott J.; Borgman, Christa; Park, Seung Il; Kim, Hyeong Ryul; Padera, Robert; Marto, Jarrod A.; Gray, Nathanael S.; Kung, Andrew L.; Shapiro, Geoffrey I.; Jänne, Pasi A.; Wong, Kwok Kin.

In: Cancer Research, Vol. 70, No. 23, 01.12.2010, p. 9827-9836.

Research output: Contribution to journalArticle

Chen, Z, Sasaki, T, Tan, X, Carretero, J, Shimamura, T, Li, D, Xu, C, Wang, Y, Adelmant, GO, Capelletti, M, Lee, HJ, Rodig, SJ, Borgman, C, Park, SI, Kim, HR, Padera, R, Marto, JA, Gray, NS, Kung, AL, Shapiro, GI, Jänne, PA & Wong, KK 2010, 'Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene', Cancer Research, vol. 70, no. 23, pp. 9827-9836. https://doi.org/10.1158/0008-5472.CAN-10-1671
Chen, Zhao ; Sasaki, Takaaki ; Tan, Xiaohong ; Carretero, Julian ; Shimamura, Takeshi ; Li, Danan ; Xu, Chunxiao ; Wang, Yuchuan ; Adelmant, Guillaume O. ; Capelletti, Marzia ; Lee, Hyun Joo ; Rodig, Scott J. ; Borgman, Christa ; Park, Seung Il ; Kim, Hyeong Ryul ; Padera, Robert ; Marto, Jarrod A. ; Gray, Nathanael S. ; Kung, Andrew L. ; Shapiro, Geoffrey I. ; Jänne, Pasi A. ; Wong, Kwok Kin. / Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene. In: Cancer Research. 2010 ; Vol. 70, No. 23. pp. 9827-9836.
@article{798ebca2c02b4e3e8566699eab36f4b5,
title = "Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene",
abstract = "Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3{\%} to 13{\%} of non-small cell lung cancer patients and rarely coexist with KRAS or EGFR mutations. To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises. In this model, the ALK kinase inhibitor TAE684 produced greater tumor regression and improved overall survival compared with carboplatin and paclitaxel, representing clinical standard of care. 18F-FDG-PET-CT scans revealed almost complete inhibition of tumor metabolic activity within 24 hours of TAE684 exposure. In contrast, combined inhibition of the PI3K/AKT and MEK/ERK1/2 pathways did not result in significant tumor regression. We identified EML4-ALK in complex with multiple cellular chaperones including HSP90. In support of a functional reliance, treatment with geldanamycin-based HSP90 inhibitors resulted in rapid degradation of EML4-ALK in vitro and substantial, albeit transient, tumor regression in vivo. Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement.",
author = "Zhao Chen and Takaaki Sasaki and Xiaohong Tan and Julian Carretero and Takeshi Shimamura and Danan Li and Chunxiao Xu and Yuchuan Wang and Adelmant, {Guillaume O.} and Marzia Capelletti and Lee, {Hyun Joo} and Rodig, {Scott J.} and Christa Borgman and Park, {Seung Il} and Kim, {Hyeong Ryul} and Robert Padera and Marto, {Jarrod A.} and Gray, {Nathanael S.} and Kung, {Andrew L.} and Shapiro, {Geoffrey I.} and J{\"a}nne, {Pasi A.} and Wong, {Kwok Kin}",
year = "2010",
month = "12",
day = "1",
doi = "10.1158/0008-5472.CAN-10-1671",
language = "English (US)",
volume = "70",
pages = "9827--9836",
journal = "Journal of Cancer Research",
issn = "0099-7013",
publisher = "American Association for Cancer Research Inc.",
number = "23",

}

TY - JOUR

T1 - Inhibition of ALK, PI3K/MEK, and HSP90 in murine lung adenocarcinoma induced by EML4-ALK fusion oncogene

AU - Chen, Zhao

AU - Sasaki, Takaaki

AU - Tan, Xiaohong

AU - Carretero, Julian

AU - Shimamura, Takeshi

AU - Li, Danan

AU - Xu, Chunxiao

AU - Wang, Yuchuan

AU - Adelmant, Guillaume O.

AU - Capelletti, Marzia

AU - Lee, Hyun Joo

AU - Rodig, Scott J.

AU - Borgman, Christa

AU - Park, Seung Il

AU - Kim, Hyeong Ryul

AU - Padera, Robert

AU - Marto, Jarrod A.

AU - Gray, Nathanael S.

AU - Kung, Andrew L.

AU - Shapiro, Geoffrey I.

AU - Jänne, Pasi A.

AU - Wong, Kwok Kin

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 13% of non-small cell lung cancer patients and rarely coexist with KRAS or EGFR mutations. To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises. In this model, the ALK kinase inhibitor TAE684 produced greater tumor regression and improved overall survival compared with carboplatin and paclitaxel, representing clinical standard of care. 18F-FDG-PET-CT scans revealed almost complete inhibition of tumor metabolic activity within 24 hours of TAE684 exposure. In contrast, combined inhibition of the PI3K/AKT and MEK/ERK1/2 pathways did not result in significant tumor regression. We identified EML4-ALK in complex with multiple cellular chaperones including HSP90. In support of a functional reliance, treatment with geldanamycin-based HSP90 inhibitors resulted in rapid degradation of EML4-ALK in vitro and substantial, albeit transient, tumor regression in vivo. Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement.

AB - Genetic rearrangements of the anaplastic lymphoma kinase (ALK) kinase occur in 3% to 13% of non-small cell lung cancer patients and rarely coexist with KRAS or EGFR mutations. To evaluate potential treatment strategies for lung cancers driven by an activated EML4-ALK chimeric oncogene, we generated a genetically engineered mouse model that phenocopies the human disease where this rearranged gene arises. In this model, the ALK kinase inhibitor TAE684 produced greater tumor regression and improved overall survival compared with carboplatin and paclitaxel, representing clinical standard of care. 18F-FDG-PET-CT scans revealed almost complete inhibition of tumor metabolic activity within 24 hours of TAE684 exposure. In contrast, combined inhibition of the PI3K/AKT and MEK/ERK1/2 pathways did not result in significant tumor regression. We identified EML4-ALK in complex with multiple cellular chaperones including HSP90. In support of a functional reliance, treatment with geldanamycin-based HSP90 inhibitors resulted in rapid degradation of EML4-ALK in vitro and substantial, albeit transient, tumor regression in vivo. Taken together, our findings define a murine model that offers a reliable platform for the preclinical comparison of combinatorial treatment approaches for lung cancer characterized by ALK rearrangement.

UR - http://www.scopus.com/inward/record.url?scp=78649973178&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78649973178&partnerID=8YFLogxK

U2 - 10.1158/0008-5472.CAN-10-1671

DO - 10.1158/0008-5472.CAN-10-1671

M3 - Article

C2 - 20952506

AN - SCOPUS:78649973178

VL - 70

SP - 9827

EP - 9836

JO - Journal of Cancer Research

JF - Journal of Cancer Research

SN - 0099-7013

IS - 23

ER -